FDA has announced it has approved Linzess (linaclotide) to treat chronic idiopathic constipation and to treat irritable bowel syndrome with constipation in adults, according to a news release. Linzess ...
The FDA has approved linaclotide (Linzess) for children aged 7 years or older with irritable bowel syndrome with constipation (IBS-C), making it the first approved treatment for pediatric IBS-C. The ...
Findings showed 30% of patients taking linaclotide 145mcg achieved the primary endpoint of combined responder. The Food and Drug Administration (FDA) has approved Linzess ® (linaclotide) for the ...
If approved, linaclotide would be the first prescription therapy for functional constipation in children and adolescents 6 to 17 years of age 1 Submission is based on positive Phase 3 study data ...
BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD), a GI-focused healthcare company, today announced that the U.S. Food and Drug Administration (FDA) approved a revised label for ...
Many Medicare Part D plans cover Linzess, but out-of-pocket costs can vary because private insurance companies manage these plans. Linzess is an expensive medication with no generic alternatives ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results